Navigation Links
MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
Date:3/28/2008

ORCHARD PARK, NY, March 28 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced its Board of Directors approved the appointment of David T. DiGiacinto as President and Chief Operating Officer, effective April 1, 2008, when he will take over the day-to-day operations of the Company. Mr. DiGiacinto's appointment is the first step in a transition in which he will become Chief Executive Officer of the Company beginning on January 1, 2009. William H. Burns, Jr. will continue to serve as Chief Executive Officer through the end of the year and has agreed to continue serving as Chairman of the Board of Directors until the Company's 2009 annual meeting, on terms and conditions which have not been finalized but which are expected to be determined within the next two months. It is anticipated he will also continue to serve on the Scientific Advisory Board of the Company during the transition and after his term as Chairman expires.

Mr. DiGiacinto is joining Minrad from Spencer Trask & Co., a private equity firm based in New York City, where he served as a Senior Managing Director. Spencer Trask invests primarily in early stage companies with technologies in a variety of market segments. Mr. DiGiacinto was mainly focused on Healthcare, Specialty Chemicals, Nutritionals and Food Ingredients. Spencer Trask Specialty Group LLC, an affiliate of Spencer Trask & Co., was an early stage investor in Minrad, Inc. in 1999 and provided the primary financing to Minrad through 2002. Mr. DiGiacinto currently serves as an advisor to the Company and has been a member of the Board of Directors since 2004. He will continue to serve as a director of the Company after assuming his new position.

Prior to joining Spencer Trask in 2000, Mr. DiGiacinto spent 18 years at Pfizer, Inc. While with Pfizer, he performed several operational and management functions both in the U.S. and Internationally. These included serving as its Director of Marketing in charge of a variety of products, including bulk antibiotics; profit and loss responsibility over its Latin American Division; and management of it's Worldwide Brewery and Dairy Division, which included both manufacturing and packaging sites. Mr. DiGiacinto is a graduate of the U.S. Military Academy at West Point. After graduation, he spent nearly seven years serving as a pilot in the U.S. Air Force. After leaving the service, he flew for a year commercially before joining Pfizer.

In order to ensure an orderly transition and to assist Mr. DiGiacinto in his new role, William H. Burns, Jr. will continue to serve as Chief Executive Officer through the end of the year. In addition to assisting Mr. DiGiacinto in his transition to Chief Executive Officer, Mr. Burns will continue to be responsible for strategic initiatives of the Company, including the expansion of its international operations, its conscious sedation program and implementing the strategy to secure the anesthesia business of the group purchasing organizations in the United States. Mr. DiGiacinto stated "Bill Burns and I have worked together over the past eight years to help Minrad move from an early stage company to a company publicly traded on the American Stock Exchange. I am excited to begin this new role at Minrad, and look forward to our working together over the next year to continue the company's development.

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB, filed with the Securities and Exchange Commission on March 29, 2007. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

Contact: Charles T. Trego, Jr.; Executive V.P. and CFO

ctrego@minrad.com

(716) 855-1068

http://www.minrad.com


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
6. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
7. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They ... a complex biological network, a depiction of a system of linkages and connections ... Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being enlisted ... bacteria that live in and on the human body –and are believed ... The Microbiome Immunity ... human microbiome, starting with the gut. The project's goal is to help ... credit: IBM ...
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
Breaking Biology News(10 mins):